Data regarding overdose of idecabtagene vicleucel is not readily available.L32858 However, patients experiencing an overdose may experience and increased risk and severity of adverse effects including cytokine release syndrome, infection, fatigue, and musculoskeletal pain.L32858 Patients should be treated with symptomatic and supportive measures.
Multiple myeloma is a cancer where plasma cells rapidly divide out of control.A232563 These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.A232563 Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide,A232593 a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal antibody like isatuximab.A232608
Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like axicabtagene ciloleucel and brexucabtagene autoleucel.A232558,A232563,L32858 These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen.A232558 The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3? T-cell activation domain, and 4-1BB costimulatory domain.L32858 Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma.L32858
Idecabtagene vicleucel was approved by the FDA on March 26, 2021 L32863 and by the EMA on August 18, 2021.L51003
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idecabtagene vicleucel. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Idecabtagene vicleucel. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Idecabtagene vicleucel. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idecabtagene vicleucel. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Quinisocaine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Idecabtagene vicleucel is combined with Etrasimod. |